CANAVAN DISEASE

Canavan Disease — a fatal progressive leukodystrophy where no treatment exists and prevention through carrier screening is the only intervention, with carrier frequency of 1 in 40 in Ashkenazi Jewish populations.

Whole genome sequencing reads the complete ASPA gene, identifying all pathogenic variants — including the rare non-Ashkenazi alleles missed by panels designed for Ashkenazi carrier screening — for accurate reproductive risk counseling across all ancestries.

ASPA

About this condition

Canavan Disease

Canavan disease is an autosomal recessive leukodystrophy caused by pathogenic variants in ASPA (aspartoacylase) on chromosome 17p13.2. ASPA encodes the enzyme aspartoacylase, which hydrolyzes N-acetylaspartate (NAA) in the brain. Deficiency of aspartoacylase leads to NAA accumulation, which impairs myelin formation and causes progressive spongy degeneration of white matter. Classic Canavan disease presents in infancy: developmental regression begins at 3-6 months of age, with macrocephaly, severe hypotonia, poor head control, progressive loss of motor milestones, visual impairment, and seizures. There is no effective treatment, and affected children typically die in the first decade of life.

Canavan disease is significantly enriched in the Ashkenazi Jewish population. Two pathogenic variants account for the vast majority of Ashkenazi disease alleles: p.Glu285Ala (E285A) and p.Tyr231Ter (Y231X), collectively accounting for approximately 97-98% of Ashkenazi ASPA pathogenic alleles. The combined carrier frequency in Ashkenazi Jewish individuals is approximately 1 in 40-55, making it one of the high-priority conditions for Ashkenazi carrier screening programs alongside Tay-Sachs, Gaucher disease, Fanconi anemia, Bloom syndrome, and others. In non-Ashkenazi populations, carrier frequency is approximately 1 in 300-400, with a broader and less characterized spectrum of rare ASPA variants, making the two-variant Ashkenazi panel inadequate for pan-ethnic carrier screening.

Carrier screening for Canavan disease allows at-risk couples — both partners are carriers — to access preimplantation genetic testing (PGT-M) with IVF, prenatal diagnosis by chorionic villus sampling or amniocentesis, or informed reproductive decision-making. Gene therapy using AAV vectors to deliver functional ASPA to the CNS has shown some biochemical efficacy in early clinical studies but has not yet demonstrated meaningful clinical improvement in affected patients. Canavan disease serves as a paradigm for the value of carrier screening programs — in the absence of effective treatment, prevention through identification of carrier couples is the only intervention that reliably changes outcomes.

Gene locus: ASPA (17p13.2)

Two-variant Ashkenazi panels detect 97-98% of Ashkenazi ASPA alleles but have poor sensitivity in non-Ashkenazi populations. Complete ASPA gene sequencing is needed for accurate carrier screening across all ancestries.

Non-Ashkenazi carrier couples are missed by Ashkenazi two-variant ASPA panels

Canavan disease carrier screening programs designed for Ashkenazi Jewish populations test for E285A and Y231X — the two variants that account for approximately 97-98% of Ashkenazi ASPA pathogenic alleles. When these panels are applied to non-Ashkenazi individuals — or in mixed Ashkenazi/non-Ashkenazi couples — the sensitivity is substantially lower. A documented case pattern exists of non-Ashkenazi couples in whom one partner tested carrier-positive on the Ashkenazi panel and the other tested negative, but who subsequently had an affected child because the non-Ashkenazi partner carried a rare ASPA variant not included on the limited panel. Whole genome sequencing reads the complete ASPA coding sequence, providing equivalent sensitivity regardless of ancestry.

Carrier screening results before pregnancy enable the full spectrum of reproductive options — results during pregnancy compress available choices

Canavan carrier couples who are identified preconceptionally can access the complete reproductive options menu: IVF with PGT-M (guaranteed unaffected embryo selection), natural conception with prenatal diagnosis by CVS or amniocentesis, donor gametes, adoption, or acceptance of risk. Couples who receive carrier results after pregnancy conception are limited to prenatal diagnosis and termination or continuation of pregnancy — a more constrained and often more emotionally difficult set of decisions. Preconception carrier screening through whole genome sequencing provides results in the ideal window for fully informed reproductive planning.

Canavan Disease — a fatal progressive leukodystrophy where no treatment exists and prevention through carrier screening is the only intervention, with carrier frequency of 1 in 40 in Ashkenazi Jewish populations.

Canavan Disease

Two-variant Ashkenazi panels detect 97-98% of Ashkenazi ASPA alleles but have poor sensitivity in non-Ashkenazi populations. Complete ASPA gene sequencing is needed for accurate carrier screening across all ancestries.

Non-Ashkenazi carrier couples are missed by Ashkenazi two-variant ASPA panels

Carrier screening results before pregnancy enable the full spectrum of reproductive options — results during pregnancy compress available choices

Others in Rare Diseases

One test. A lifetime of answers.